Towards clinical use of targeted therapies for liver fibrosis: development of a sustained release formulation for therapeutic proteins

被引：1
|
作者：
Van Dijk, F. [1 ,2 ]
Teekamp, N. [2 ]
Beljaars, L. [1 ]
Post, E. [1 ]
Schuppan, D. [3 ,4 ,5 ]
Kim, Y. O. [3 ,4 ]
Poelstra, K. [1 ]
Frijlink, E. [2 ]
Hinrichs, W. [2 ]
Olinga, P. [2 ]
机构：
[1] Univ Groningen, Pharmacokinet Toxicol & Targeting, Groningen, Netherlands
[2] Univ Groningen, Pharmaceut Technol & Biopharm, Groningen, Netherlands
[3] Johannes Gutenberg Univ Mainz, Inst Translat Immunol, Mainz, Germany
[4] Johannes Gutenberg Univ Mainz, Res Ctr Immune Therapy, Mainz, Germany
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30350-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PS-074
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 10 条
  • [1] Therapeutic proteins in the treatment of liver fibrosis: the antifibrotic potential of a sustained release formulation for a PDGFβ-receptor targeted rho-kinase inhibitor
    van Dijk, Fransien
    Teekamp, Naomi
    Beljaars, Leonie
    Post, Eduard
    Kim, Yong Ook
    Frijlink, Erik
    Hinrichs, Wouter
    Schuppan, Detlef
    Poelstra, Klaas
    Olinga, Peter
    HEPATOLOGY, 2017, 66 : 217A - 217A
  • [2] Clinical Advancements in the Targeted Therapies against Liver Fibrosis
    Bansal, Ruchi
    Nagorniewicz, Beata
    Prakash, Jai
    MEDIATORS OF INFLAMMATION, 2016, 2016
  • [3] Editorial: Clinical Therapeutic Development Against Cancers Resistant to Targeted Therapies
    Zhou, Fanfan
    Zhu, Hong
    Fu, Caiyun
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [4] Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver
    van Dijk, F.
    Teekamp, N.
    Beljaars, L.
    Post, E.
    Zuidema, J.
    Steendam, R.
    Kim, Y. O.
    Frijlink, H. W.
    Schuppand, D.
    Poelstra, K.
    Hinrichs, W. L. J.
    Olinga, P.
    JOURNAL OF CONTROLLED RELEASE, 2018, 269 : 258 - 265
  • [5] Lactosylated PLGA nanoparticles containing ε-polylysine for the sustained release and liver-targeted delivery of the negatively charged proteins
    Zhou, Ping
    An, Tong
    Zhao, Chuan
    Li, Yuan
    Li, Rongshan
    Yang, Rui
    Wang, Yinsong
    Gao, Xiujun
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 478 (02) : 633 - 643
  • [6] AAV-mediated homology-independent targeted integration leads to sustained secretion of therapeutic proteins from new-born liver
    Esposito, F.
    Dell'Aquila, F.
    Ferla, R.
    Horrach, P. Sureda
    Auricchio, S.
    Dell'Anno, M.
    Llado, M.
    Nusco, E.
    Auricchio, A.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A11 - A11
  • [7] Potential Use of Polyvinyl Acetate-Polyvinylpyrrolidone Mixture for the Development of Atenolol Sustained Release Matrix Tablets: Optimization of Formulation through in Vitro-in Vivo Assessment Study
    Owayez, Ali Saeed
    Abd El-Ghany, Galal Mahmoud
    Abu Hashim, Irhan Ibrahim
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2017, 65 (06) : 545 - 557
  • [8] A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence
    Nasser, Azmi F.
    Heidbreder, Christian
    Gomeni, Roberto
    Fudala, Paul J.
    Zheng, Bo
    Greenwald, Mark K.
    CLINICAL PHARMACOKINETICS, 2014, 53 (09) : 813 - 824
  • [9] A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence
    Azmi F. Nasser
    Christian Heidbreder
    Roberto Gomeni
    Paul J. Fudala
    Bo Zheng
    Mark K. Greenwald
    Clinical Pharmacokinetics, 2014, 53 : 813 - 824
  • [10] The clinical trend of non-alcoholic fatty liver disease (NAFLD) fibrosis score with sustained use of glucagon-like peptide 1 agonist (GLP-1a) therapy in patients with Type 2 diabetes
    Waqqas, R.
    Nayak, A. U.
    Walker, A. B.
    Varadhan, L.
    DIABETIC MEDICINE, 2015, 32 : 159 - 159
1